|Product||Target||Indication||Lead OpPreclinPhase 1Phase 2Phase 3|
type 1 receptor
|Acute Heart Failure||intravenous|
|Moderate to Severe Pain||oral|
|Parkinson's, Migraine, Neuropathic Pain|
TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. Trevena is developing TRV130 for the treatment of moderate to severe acute pain where intravenous therapy is preferred, with a clinical development focus in acute postoperative pain.
Dr. Michael Lark, CSO, will be attending the American Society of Regional Anesthesia and Pain 13th Annual Pain Medicine Meeting in San Francisco, California from 13th to 16th of November 2014.
Details on the meeting, can be found at the ASRA website.
Copyright © Trevena, Inc.